Clinical Trials Logo

Papillary Renal Cell Carcinoma clinical trials

View clinical trials related to Papillary Renal Cell Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03635892 Active, not recruiting - Clinical trials for Papillary Renal Cell Carcinoma

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.

NCT ID: NCT03541902 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Start date: May 15, 2018
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC. The study doctor can explain how the study drugs are designed to work. Up to 84 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT01767636 Active, not recruiting - Clinical trials for Stage IV Renal Cell Cancer

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Start date: May 16, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor.